AAREY DRUGS PHARMACEUTICALS LTD Q1 RESULTS

Nifty gained 1.2%, driven by IT, energy, and pharma stocks. U.S. labor data, TCS earnings, Rupee vs. Dollar, Bank Nifty, oil prices, FIIs, IPO action, and dividends will influence markets next week. Bulls maintain strength with positive sentiment an...

An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (...

Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.

Torrent Pharmaceuticals Ltd on Friday reported a 56.45 per cent jump in consolidated net profit to Rs 449 crore in the March quarter, riding on higher revenue.

Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.

Biocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio to address weight management needs and tapping into a USD 47 million market opportunity. Biocon said the total ...

In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 c...

The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.

Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.

The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.

Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.

Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the...

Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.

Rising temperatures across various regions of India are driving increased demand for medications aimed at managing chronic conditions. This includes prescriptions for high blood pressure (antihypertensives), cholesterol (lipid-lowering drugs), and b...

Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.

Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.​​

Dr Reddy's has reported a 36% year-on-year jump in quarterly net profit, helped by increase in volumes of base business, new product launches, partially offset by price erosion in certain markets.

Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.

Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. For the year ended March 31, 2024, the company posted a consolidated net pr...